Name: Mendus Q1: CEO Interview
Uploaded: 2025-05-07T06:08:35.811Z
Description: Immunotherapy remains a game-changer in the rapidly evolving landscape of cancer treatment. Leading this wave of innovation is Mendus, which released its Q1 report yesterday (6/5). To discuss the report and key developments from the quarter, we spoke with CEO Erik Manting in an exclusive interview.

videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    summary
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
      transcript {
        segments {
          speakerId
          speakerName
          sentences {
            start
            end
            text
          }
        }
        speakers {
          speakerId
          name
        }
      }
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

first

order

upcoming

edges

Community Manager

Jesper Hagman

Mendus

Immunotherapy remains a game-changer in the rapidly evolving landscape of cancer treatment. Leading this wave of innovation is Mendus, which released its Q1 report yesterday (6/5). To discuss the report and key developments from the quarter, we spoke with CEO Erik Manting in an exclusive interview.



<p class data-start="54" data-end="343">Immunotherapy remains a game-changer in the rapidly evolving landscape of cancer treatment. Leading this wave of innovation is Mendus, which released its Q1 report yesterday (6/5). To discuss the report and key developments from the quarter, we spoke with CEO Erik Manting in an exclusive interview.</p>
<h3 data-start="345" data-end="476"><a href="https://www.inderes.se/videos/mendus-audiocast-q125" target="_blank" rel="noopener">Watch the Q1 presentation from Mendus here.&#xa0;</a></h3>
<div class="Layouts_gridColumn__2CfdR inline-grid">
<div class="SanitizedContent_content__gjYVu">
<h3><strong>F&#xf6;lj oss p&#xe5;:</strong></h3>
<ul class="ul1">
<li class="li2"><span class="s1"><a href="https://twitter.com/InderesNordic"><span class="s2"><strong>X (Twitter)</strong></span></a></span></li>
<li class="li2"><span class="s1"><a href="https://www.instagram.com/inderes.se"><span class="s2"><strong>Instagram</strong></span></a></span></li>
<li class="li2"><span class="s1"><a href="https://www.tiktok.com/@inderes.se"><span class="s2"><strong>TikTok</strong></span></a></span></li>
</ul>
<p class="p2"><strong>Du &#xe4;r hj&#xe4;rtligt v&#xe4;lkommen att ansluta dig till v&#xe5;r kostnadsfria community och delta i heta aktiediskussioner p&#xe5;&#xa0;</strong><a href="https://forum.inderes.se/"><span class="s3"><strong>forumet</strong></span></a></p>
</div>
</div>

Inderes

Mendus Q1: CEO Interview

F-Secure

F-Secure, Investor Deep Dive

Clas Ohlson

Clas Ohlson AB, CMD

BioMar Group

Michael Friis taler med Carlos Diaz, CEO i BioMar

Presentation of BioMar

Novo Nordisk

Genmab

Danish Aerospace and Defence Company

Hafnia

FLSmidth & Co.

Swiss Properties Invest

Rockwool

Ambu

Bavarian Nordic

HCA Morgenbørs 03/06 - Overvejende negative markeder og fokus på Genmab og Novo Nordisk

Mendus Q1: CEO Interview

Watch the Q1 presentation from Mendus here.

Följ oss på:

Stay up to date

Upcoming webcasts

Mendus Q1: CEO Interview

Watch the Q1 presentation from Mendus here.

Följ oss på:

Stay up to date

Recent videos

Upcoming webcasts

Recent videos